AR080872A1 - Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad - Google Patents

Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad

Info

Publication number
AR080872A1
AR080872A1 ARP110101192A ARP110101192A AR080872A1 AR 080872 A1 AR080872 A1 AR 080872A1 AR P110101192 A ARP110101192 A AR P110101192A AR P110101192 A ARP110101192 A AR P110101192A AR 080872 A1 AR080872 A1 AR 080872A1
Authority
AR
Argentina
Prior art keywords
treatment
biomarcators
disease
mdm2 inhibitors
subject
Prior art date
Application number
ARP110101192A
Other languages
English (en)
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of AR080872A1 publication Critical patent/AR080872A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia

Abstract

Métodos para seleccionar y tratar a un sujeto con leucemia, en los que el sujeto se selecciona para tratamiento y se trata con inhibidor de MDM2 debido a que las células de dicho sujeto contienen una mutacion FLT-3-ITD. Reivindicacion 11: El método de una cualquiera de las reivindicaciones 1-10, en el que el inhibidor de MDM2 es un inhibidor de MDM2 de espiro-oxindol.
ARP110101192A 2010-04-09 2011-04-08 Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad AR080872A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32259210P 2010-04-09 2010-04-09
US201161451956P 2011-03-11 2011-03-11

Publications (1)

Publication Number Publication Date
AR080872A1 true AR080872A1 (es) 2012-05-16

Family

ID=44761387

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101192A AR080872A1 (es) 2010-04-09 2011-04-08 Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad

Country Status (14)

Country Link
US (1) US20110251252A1 (es)
EP (1) EP2563360A4 (es)
JP (1) JP2013523820A (es)
KR (1) KR20130050938A (es)
CN (1) CN103153302A (es)
AR (1) AR080872A1 (es)
AU (1) AU2011237782A1 (es)
CA (1) CA2800519A1 (es)
IL (1) IL222234A0 (es)
MX (1) MX2012011600A (es)
RU (1) RU2012147597A (es)
SG (1) SG184288A1 (es)
TN (1) TN2012000450A1 (es)
WO (1) WO2011127058A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
NZ600430A (en) * 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
EA201390682A1 (ru) * 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
MY172862A (en) 2011-03-10 2019-12-13 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivatives
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
JP6450191B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド ペプチドミメティック大環状化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR101418970B1 (ko) 2013-03-20 2014-07-11 (주)제욱 야생형 EGFR를 가진 비소세포폐암에서 EGFR 억제제와 c-MET 억제제 병용투여에 대한 반응 예측 인자
ES2785203T3 (es) * 2013-12-05 2020-10-06 Hoffmann La Roche Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA)
AU2015247646B2 (en) * 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
WO2016028391A2 (en) * 2014-08-18 2016-02-25 Hudson Biopharma Inc. Spiropyrrolidines as mdm2 inhibitors
KR102570210B1 (ko) 2014-09-24 2023-08-23 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 제제
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
US20170227544A1 (en) * 2014-10-10 2017-08-10 Hoffmann-La Roche Inc. Methods for personalizing patient cancer therapy with an mdm2 antagonist
JP6564449B2 (ja) * 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US10565717B2 (en) 2016-03-01 2020-02-18 Magic Leap, Inc. Depth sensing systems and methods
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
RU2763141C1 (ru) * 2021-06-29 2021-12-27 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Этил (3r*,3a'r*,8a'r*,8b's*)-1',2,3'-триоксо-2',5-дифенил-1-(4-хлорфенил)-1,2,2',3',3a',6',7',8',8a',8b'-декагидро-1'h-спиро[пиррол-3,4'-пирроло[3,4-a]пирролизин]-4-карбоксилат, обладающий противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176463A1 (en) * 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
EA019566B1 (ru) * 2005-02-22 2014-04-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Низкомолекулярные ингибиторы mdm2
JP5399904B2 (ja) * 2006-08-30 2014-01-29 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
NZ600430A (en) * 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists

Also Published As

Publication number Publication date
JP2013523820A (ja) 2013-06-17
CA2800519A1 (en) 2011-10-13
RU2012147597A (ru) 2014-05-20
WO2011127058A2 (en) 2011-10-13
CN103153302A (zh) 2013-06-12
SG184288A1 (en) 2012-11-29
AU2011237782A1 (en) 2012-10-25
KR20130050938A (ko) 2013-05-16
EP2563360A2 (en) 2013-03-06
EP2563360A4 (en) 2015-12-16
WO2011127058A8 (en) 2011-12-01
US20110251252A1 (en) 2011-10-13
TN2012000450A1 (en) 2014-01-30
MX2012011600A (es) 2012-11-30
IL222234A0 (en) 2012-12-31
WO2011127058A9 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
AR080872A1 (es) Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad
CO2019002237A2 (es) Inhibidores de procesos metabólicos celulares
CL2018000685A1 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
AR097032A1 (es) Hidrogeles de poli(alquenilamida)-polisacárido para el tratamiento de formaciones subterráneas
UY33925A (es) Inhibidores tricíclicos de quinasas
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
UY32049A (es) Inhibidores de cmet
ECSP13013084A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
UY33969A (es) Inhibidores tricíclicos fusionados dobles de las cdk 4/6 y de la flt3
PH12016500768B1 (en) Methods of treating and preventing graft versus host disease
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
UY34230A (es) Terapia de combinación para tumores malignos de células b cd19+ que comprende un inmunoconjugado maitansinoide anti-cd19 y rituximab
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
UY33959A (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7
CL2017000104A1 (es) Compuestos novedosos de pirimidina sustituidos.
PE20151494A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
AR064108A1 (es) Tratamiento de ansiedad con eszopiclona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal